An orally active synthetic small-molecule AdipoR agonist identified by screening a library of candidate compounds29, AdipoRon is shown to activate AMPK and PPAR-α pathways22,29, ameliorate insulin resistance and glucose intolerance22,29, and reverse life shortening in obese diabetic mice29. This evidence concerns the gene PPARA and glucose measurement.